

COMMENTARY

Acetazolamide for central sleep apnea: teaching an old drug new tricks?

Commentary on Ni Y-N, Yang H, Thomas RJ. The role of acetazolamide in sleep apnea at sea level: a systematic review and meta-analysis. *J Clin Sleep Med*. 2021;17(6):1295–1304. doi:10.5664/jcsm.9116

Lee K. Brown, MD, FAASM^{1,2}

¹Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico;

²Program in Sleep Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico

Acetazolamide is an old drug. A very old drug. In fact, the method by which it may be synthesized (along with a number of other molecules related to 5-membered heterocyclic sulfonamides having at least 3-hetero atoms) was patented in 1951, one year after I was born. The genesis for synthesizing acetazolamide and its related molecules was the discovery that sulfanilamide exhibited activity (albeit weak) as a carbonic anhydrase inhibitor, and the resulting diuretic property prompted its experimental use in heart failure in the late 1940s. Thus, the impetus existed to determine whether other heterocyclic sulfonamides could be identified that exhibited more potent carbonic anhydrase inhibitor activity and consequently might find use in the treatment of human disease. Indeed, several such molecules were synthesized; at least 8, including acetazolamide, have been available clinically although not all are as closely related to sulfonamides.

Carbonic anhydrase is a conserved zinc metalloprotease present in both prokaryotes and eukaryotes and has many isoforms.¹ Human cells contain only carbonic anhydrase α -isoforms, and there are actually 14 of these; α -isoforms of carbonic anhydrase are ubiquitous in cells throughout the human body and may be cytosolic, membrane-bound, mitochondrial, or secretory. Moreover, although it is primarily considered to catalyze the reaction $\text{HCO}_3^- + \text{H}^+ \leftrightarrow \text{CO}_2 + \text{H}_2\text{O}$, it seems to serve important functions seemingly unrelated to this activity, including roles in adipogenesis (it regulates PPAR γ 2 expression) and gluconeogenesis.

Acetazolamide is a nonspecific CAI and could potentially affect all isoforms in all cells and in various ways. It is no surprise, therefore, that acetazolamide has found uses that are both on-label (edema resulting from heart failure or drug-induced; epilepsies; glaucoma) and off-label (intracranial hypertension, hypercapnia, and/or weaning from mechanical ventilation in patients with chronic obstructive pulmonary disease; obesity hypoventilation syndrome; methotrexate toxicity; contrast-induced nephropathy; nephrolithiasis), most of which may be attributed to the primary mechanism of action and some perhaps to other effects.^{2,3} The use of acetazolamide in disorders of respiration has always been attributed to promoting

bicarbonate excretion in the proximal tubule of the kidney by means of the above reaction. However, attention should be paid to the diverse actions of this drug when inconsistent results emerge from its use in studies of sleep-disordered breathing.

In this issue of the *Journal of Clinical Sleep Medicine*, Ni et al⁴ have performed the difficult task of identifying published reports of acetazolamide employed for the treatment of obstructive sleep apnea (OSA) or central sleep apnea (CSA) in patients at or close to sea level. They rightly limited their meta-analysis to studies of reasonably high-quality methodology: 6 randomized controlled trials using either a placebo or another drug as a control, and 9 studies in which patients acted as their own controls (“pre- and post-acetazolamide”). Unfortunately, even after culling the most methodologically challenged reports, they were still left with a *gemisch* of 15 publications that varied in methodology, sufficient numbers of patients, results stated as only “sleep apnea” but not specifically CSA or OSA, and reports involving a broad variety of clinical scenarios including heart failure,³ spinal cord injury,¹ and opioid use.¹ Eight articles reported exclusively on CSA (including the studies of spinal cord injury and opioid use), and only 2 studies were limited to patients with OSA. One of the 15 articles included the use of continuous positive airway pressure and was excluded, leaving 14 to be incorporated into the meta-analysis. Moreover, the studies were heterogeneous with respect to the outcomes reported; only 6 reported the central apnea index and one-half or fewer reported oxyhemoglobin saturation variables or respiratory-related arousal indices.

As is standard practice in a meta-analysis, the authors analyzed the studies for bias. Six had no bias in attribution, detection, or reporting, whereas 9 were found with high bias in selection, performance, and detection. In addition, significant heterogeneity was found in both the CSA and OSA investigations. Given the large degree of heterogeneity, the authors appropriately utilized a random-effects method to compute mean differences; because they did not use the Cochrane term *standardized mean difference*, they were presumably reporting the absolute difference between the mean values of the outcome measure(s) of the incorporated studies—that is, the estimates of

the difference in the outcome measure(s) when studies are combined not just by weighting based on the within-study variance but also by the between-study variance. This is an important difference because in using this methodology, studies with large numbers of patients but high variance are not given undue influence compared to studies with smaller numbers of patients but low variance.^{5,6}

Despite these considerations, the authors reported results that were significant, if perhaps not clinically significant, with respect to the primary outcome. Acetazolamide reduced the apnea-hypopnea index (AHI) by a mean difference of 16 events/h for the 14 studies overall. However, patients with CSA showed the greatest effect (mean decline in AHI of 23 events/h and in central apnea index of 12 events/h; this result included 2 of the 3 heart failure groups) followed by those with unclassified sleep apnea or mixed OSA and CSA (mean decrease of 8 events/h). Studies enrolling only patients with OSA showed no significant improvement in AHI overall; whereas mean AHI was reduced by 10 events/h, the 95% confidence interval bracketed 0 (−33 to +13). Clearly, the reduction in AHI reported for the group as a whole was attributable to patients with CSA and those with mixed CSA/OSA or unclassified sleep apnea; one would likely presume that the latter group included patients with a high proportion of CSA. Absent this information, it is not possible to assess the validity of this particular finding. One must also interpret these findings in the context of the baseline values of AHI to judge whether the reductions reported overall and for CSA were clinically meaningful. Focusing on CSA (the most relevant finding), the authors tabulated baseline AHIs as reported in the analyzed articles as varying between 18 events/h and 78 events/h; in this context, the small (but significant) mean difference in AHI on acetazolamide seems far less impressive. Whether these were clinically meaningful results seems doubtful. Admittedly, the individual study results (Table S1 in their study) enumerating reductions in the central AHI seemed more promising. However, acting on the results of individual studies defeats the whole purpose of a meta-analysis, which considers the number of patients in each study and the variance of the data in each study (using the random-effects method) and weights the mean difference accordingly.

Other findings of interest included a reduction in the respiratory arousal index (but only by a mean of < 1 event/h) for the group overall and improved oxygenation overall but not when the OSA and CSA studies were examined independently. Event duration did not change with acetazolamide therapy. Interestingly, acetazolamide improved total sleep time by a mean of 26 minutes and sleep efficiency by a less impressive 5%. High heterogeneity was once more present in all of the above analyses. Finally, as expected from the known primary mechanism of acetazolamide treatment, arterial pH, pCO₂, and HCO₃[−] all decreased, but with high heterogeneity involving the first 2 metrics. The mean reduction in HCO₃[−] was an impressive but expected 5.65 mEq/L.

Acetazolamide is thought to suppress hyperventilatory CSA through 2 different mechanisms. The first relates to the apneic threshold during sleep, which, has been measured to be approximately 33–35 mmHg, perilously close to normal eupneic PaCO₂ and even closer in hyperventilatory settings such as heart failure, in individuals with a particularly robust ventilatory

response to CO₂, and at high altitude. The difference between PaCO₂ and the apneic threshold for PaCO₂ is termed the CO₂ reserve, and when this value is small, minor perturbations in PaCO₂ can result in CSA. Paradoxically, although acetazolamide induces a metabolic acidosis and stimulates ventilation, Nakayama et al⁷ showed (in dogs) that although the drug causes a fall in arterial PaCO₂, it also dramatically reduces the apneic threshold for PaCO₂ during sleep. In fact, it causes a widening of CO₂ reserve, an effect that has been attributed to an increase in “background” ventilatory drive. The decrease of the apneic threshold for PaCO₂, out of proportion to the decrease in PaCO₂ induced by acetazolamide, stabilizes breathing and reduces the tendency for CSA to occur.

The second mechanism involves a decrease in plant gain associated with the hypocapnia induced by acetazolamide. Ventilation is governed by a negative feedback control system, and excessive values of loop gain (the product of controller gain and plant gain) will destabilize ventilatory control and result in periodic breathing, eg, CSA. Hypocapnia moves the relationship between minute ventilation and PaCO₂ to a different position along the “metabolic hyperbola,” graphically depicted in the seminal article by Berger et al.⁸ This curve describes the relationship between changes in minute ventilation and PaCO₂; as PaCO₂ moves further into the hypocapnic range, changes in minute ventilation result in smaller than usual changes in PaCO₂. Thus, the increased background drive produced by acetazolamide induces high minute ventilation and low PaCO₂, reduces plant gain and thus loop gain, and stabilizes breathing.⁹

The meta-analysis by Ni et al⁴ is not the only such study examining the effects of acetazolamide on sleep apnea at sea level; I was able to identify a total of 5. Two addressed OSA specifically,^{10,11} 2 examined the effect on both OSA and CSA,^{12,13} and only 1 focused exclusively on CSA.¹⁴ No meta-analysis of acetazolamide in patients with OSA or CSA resulting from opioid medication appears in the published literature. Unfortunately, 1 meta-analysis examining both OSA and CSA included several investigations performed at high altitude and is not comparable to that of Ni et al¹³; it seems from examining the other four references that the others excluded reports of studies at high altitude. None of these 5 studies specifically excluded patients with heart failure, and 1 included only patients with heart failure.¹² With respect to OSA, Mason et al¹⁰ analyzed only 1 study, which reported a substantial (and most likely clinically meaningful) decrease in AHI with acetazolamide; unfortunately, only 10 patients were enrolled. Gaisl et al¹¹ excluded reports that were not randomized controlled trials and identified only 1 such trial, which showed a modest decrease in AHI (10 events/h) in the 44 randomized patients. Wongboonsin et al¹² performed their analysis to yield a standardized mean difference, and therefore one cannot easily convert this result to a change in AHI. However, the AHI for CSA and OSA combined yielded what is considered a significantly large standardized mean difference of −1.06 and for CSA alone of −1.10.¹⁵ They did not separately report a standardized mean difference for OSA, and one can most likely infer that the fall in overall AHI was predominantly the result of the effect of acetazolamide on CSA. Moreover, their meta-analysis was limited to patients with heart failure, and although not explicitly

stated these patients seemed to primarily suffer from heart failure with reduced ejection fraction. Finally, another meta-analysis examined multiple treatment modalities for CSA and found only 1 report of the use of acetazolamide, preventing a meta-analysis focusing specifically on acetazolamide.¹⁴ Performed to develop practice parameters under the auspices of the American Academy of Sleep Medicine, this document concluded that acetazolamide might be an “option” for the treatment of primary CSA and could be “considered” for use in patients with heart failure.

In the final analysis, what can we conclude about the possible use of acetazolamide in sleep apnea? First, it seems not to be useful for OSA. Second, it seems to have a modest beneficial effect in CSA associated with several clinical scenarios, specifically heart failure, where it has the modest additional advantage of contributing to diuresis, and in primary CSA, assuming that such an entity exists.¹⁶ However, the emphasis is on “modest.” That acetazolamide is useful for CSA at high altitudes is undisputed, with evidence available from a number of studies and 1 meta-analysis.¹⁷ On the other hand, acetazolamide is by no means a benign medication with respect to significant adverse effects, many of them common: paresthesia, nausea, fatigue, and headache, to name a few. The information that the meta-analysis by Ni et al⁴ contributes to how we manage CSA points to the fact that there are better choices available and that the drug has no role in the treatment of OSA.

CITATION

Brown LK. Acetazolamide for central sleep apnea: teaching an old drug new tricks? *J Clin Sleep Med*. 2021;17(6):1153–1155.

REFERENCES

1. Kumar S, Rulhania S, Jaswal S, Monga V. Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors. *Eur J Med Chem*. 2021;209:112923.
2. Acetazolamide [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical Companies, Inc. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205358Orig1s000lbl.pdf Accessed April 2, 2021.
3. Van Berkel MA, Elefritz JL. Evaluating off-label uses of acetazolamide. *Am J Health Syst Pharm*. 2018;75(8):524–531.
4. Ni Y-N, Yang H, Thomas RJ. The role of acetazolamide in sleep apnea at sea level: a systematic review and meta-analysis. *J Clin Sleep Med*. 2021;17(6):1295–1304.
5. Deeks JJ, Higgins JPT, Altman DG; on behalf of the Cochrane Statistical Methods Group. Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, et al., eds. *Cochrane Handbook for Systematic Reviews of Interventions*, version 6.2 (updated February 2021). <https://training.cochrane.org/handbook/current/chapter-10>. Accessed April 2, 2021.

6. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. *A basic introduction to fixed-effect and random-effects models for meta-analysis*. *Res Syn Meth*. 2010;1(2):97–111.
7. Nakayama H, Smith CA, Rodman JR, Skatrud JB, Dempsey JA. Effect of ventilatory drive on carbon dioxide sensitivity below eupnea during sleep. *Am J Respir Crit Care Med*. 2002;165(9):1251–1260.
8. Berger AJ, Mitchell RA, Severinghaus JW. Regulation of respiration (third of three parts). *N Engl J Med*. 1977;297(4):194–201.
9. Dempsey JA, Smith CA, Przybylowski T, et al. The ventilatory responsiveness to CO₂ below eupnoea as a determinant of ventilatory stability in sleep. *J Physiol*. 2004;560(Pt 1):1–11.
10. Mason M, Welsh EJ, Smith I. Drug therapy for obstructive sleep apnoea in adults. *Cochrane Database Syst Rev*. 2013;(5):CD003002.
11. Gaisl T, Haile SR, Thiel S, Osswald M, Kohler M. Efficacy of pharmacotherapy for OSA in adults: a systematic review and network meta-analysis. *Sleep Med Rev*. 2019;46:74–86.
12. Wongboonsin J, Thongprayoon C, Bathini T, et al. Acetazolamide therapy in patients with heart failure: a meta-analysis. *J Clin Med*. 2019;8(3):349.
13. Schmickl CN, Landry SA, Orr JE, et al. Acetazolamide for OSA and central sleep apnea: a comprehensive systematic review and meta-analysis. *Chest*. 2020;158(6):2632–2645.
14. Aurora RN, Chowdhuri S, Ramar K, et al. The treatment of central sleep apnea syndromes in adults: practice parameters with an evidence-based literature review and meta-analyses. *Sleep*. 2012;35(1):17–40.
15. Faraone SV. Interpreting estimates of treatment effects: implications for managed care. *P T*. 2008;33(12):700–711.
16. Diaz S, Brown LK. Is idiopathic central sleep apnea a separate entity? *J Clin Sleep Med*. 2020;16(12):1999–2001.
17. Liu H-M, Chiang I-J, Kuo KN, Liou C-M, Chen C. The effect of acetazolamide on sleep apnea at high altitude: a systematic review and meta-analysis. *Ther Adv Respir Dis*. 2017;11(1):20–29.

SUBMISSION & CORRESPONDENCE INFORMATION

Submitted for publication March 29, 2021

Submitted in final revised form March 29, 2021

Accepted for publication March 29, 2021

Address correspondence to: Lee K. Brown, MD, FAASM, Sleep Disorders Centers, University of New Mexico Health System, 1101 Medical Arts Avenue NE, Building 2, Albuquerque, NM 87102; Tel: (505) 272-6110; Fax: (505) 272-6112; Email: lkbrown@salud.unm.edu

DISCLOSURE STATEMENT

Dr. Brown coedits the Sleep and Respiratory Neurobiology section of *Current Opinion in Pulmonary Medicine* and is a coauthor of a chapter on positive airway pressure treatment for obstructive sleep apnea in *UpToDate* and on obstructive sleep apnea in *Clinical Decision Support: Pulmonary Medicine and Sleep Disorders*. He serves on the Polysomnographic Practice Advisory Committee of the New Mexico Medical Board and chairs the New Mexico Advisory Board for Respiratory Care. He chairs the Board of Directors of GAMA-PAC, the political action committee of the Greater Albuquerque Medical Association.